trimetrexate has been researched along with Neoplasms in 29 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimetrexate is a promising new lipophilic antifolate with antitumor and antimicrobial activity, which is currently undergoing clinical trials." | 3.76 | Trimetrexate: a second generation folate antagonist in clinical trial. ( Bertino, JR; Lin, JT, 1987) |
| "Presently cancer is a grave health issue with predominance beyond restrictions." | 2.72 | Therapeutic progression of quinazolines as targeted chemotherapeutic agents. ( Bansal, R; Malhotra, A, 2021) |
| "If tumors are resistant to methotrexate because of decreased transport of drug (and also folate), then the same pharmacological principle used to develop TMTX/LV for the treatment of P." | 2.69 | High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? ( Holcenberg, JS; Hum, M; Kamen, BA; Tkaczewski, I; Weaver, JW; Wilson, J, 1998) |
| "Trimetrexate (TMTX) is a second generation antifol with predominantly nonrenal elimination and antitumor activity superior to that of methotrexate in preclinical models." | 2.67 | Pharmacokinetic study of trimetrexate in combination with cisplatin. ( Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J, 1991) |
| " The dosage schedule was single-dose intravenous administration (single treatment), followed by one or two courses of 5-day intravenous administration (5-day treatment) at 3-week intervals." | 2.67 | [Phase I study of CI-898. CI-898 Study Group]. ( Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M, 1991) |
| "Trimetrexate is an agent that does not require uptake by the folate carrier transport system, a major mechanism of cellular resistance both in vitro and in vivo." | 2.39 | Clinical pharmacokinetics and pharmacology of trimetrexate. ( DeLap, RJ; Marshall, JL, 1994) |
| "Many of the known anticancer drugs, including the taxoids, docetaxel (Taxotere) and paclitaxel (Taxol), are derived from natural products and there will be many more active compounds to be discovered amongst the 300000 plant species available for evaluation." | 2.39 | The development of new chemotherapeutic agents. ( Hanauske, AR, 1996) |
| "Trimetrexate (TMTX) is an analog of methotrexate and a potent inhibitor of the enzyme dihydrofolate reductase." | 1.28 | A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. ( Allegra, CJ; Balis, F; Brooks, J; Curt, GA; Drake, JC; Jenkins, J; Thomas, R; Weiss, RB, 1990) |
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| "Trimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with methotrexate and has a wide spectrum of preclinical activity." | 1.28 | A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. ( Bishop, JF; Friedlander, ML; Morris, R; Olver, IN; Raghavan, D; Reece, P, 1989) |
| " TMTX plasma concentrations were measured after the first dose and the data were fit by two- or three-compartment mammillary pharmacokinetic models." | 1.28 | A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics. ( Donehower, RC; Ettinger, DS; Grochow, LB; Noe, DA, 1989) |
| " TMTX concentrations were measured 1 and 24 hours after each dose, and the data were fit by use of a one-compartment pharmacokinetic model." | 1.28 | Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. ( Dole, GB; Donehower, RC; Ettinger, DS; Graham, ML; Grochow, LB; McGuire, WP; Noe, DA; Rowinsky, EK, 1989) |
| "Sixty-nine of 136 tumors plated for the TMQ study and 84 of 228 tumors plated for the ametantrone study were evaluable for drug-sensitivity assays." | 1.27 | Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. ( Elslager, E; Lathan, B; Von Hoff, DD, 1984) |
| " The half-life of the terminal elimination-phase was 16." | 1.27 | Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. ( Baker, M; Bertino, JR; Cashmore, AR; Delap, R; Dreyer, RN; Ernstoff, M; Grillo-Lopez, A; Lin, JT; Marsh, JC; Whitfield, LR, 1987) |
| " Dosage adjustment may have to be considered for patients who have renal dysfunction." | 1.27 | Clinical pharmacology of trimetrexate. ( Covington, WP; Ho, DH; Krakoff, IH; Legha, SS; Newman, RA, 1987) |
| " TMTX plasma levels were measured by HPLC every 3 days prior to daily dosing in patients receiving 4 mg/m2 to determine whether drug accumulation occurred during this prolonged administration schedule." | 1.27 | A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. ( Eisenhauer, E; Jolivet, J; Landry, L; McCormack, JJ; Pinard, MF; Tong, WP, 1987) |
| "Trimetrexate is a 2,4-diaminoquinazoline inhibitor of dihydrofolate reductase (DHFR) which is cytotoxic in vitro and in vivo to several tumors resistant to methotrexate." | 1.27 | Trimetrexate: clinical development of a nonclassical antifolate. ( DeLap, RJ; Grillo-Lopez, AJ; Hoth, DF; King, SA; Leyland-Jones, B; O'Dwyer, PJ, 1987) |
| " Preclinical antineoplastic activity, demonstrated schedule dependency, and data suggesting effectiveness against methotrexate-resistant cells prompted a Phase I clinical and pharmacokinetic study of trimetrexate using an i." | 1.27 | Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. ( Blow, A; Grove, WR; Haugh, LD; Lopez, AJ; Low, JB; McCormack, JJ; Roberts, JD; Stewart, JA; Tong, W; Whitfield, LR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (48.28) | 18.7374 |
| 1990's | 14 (48.28) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, R | 1 |
| Malhotra, A | 1 |
| Lathan, B | 1 |
| Von Hoff, DD | 1 |
| Elslager, E | 1 |
| Machover, D | 1 |
| Seitz, DE | 1 |
| Marshall, JL | 1 |
| DeLap, RJ | 3 |
| Pappo, AS | 1 |
| Vats, T | 1 |
| Williams, TE | 1 |
| Bernstein, M | 1 |
| Kamen, BA | 2 |
| Hanauske, AR | 1 |
| Takimoto, CH | 1 |
| Allegra, CJ | 2 |
| Hum, M | 1 |
| Holcenberg, JS | 1 |
| Tkaczewski, I | 1 |
| Weaver, JW | 1 |
| Wilson, J | 1 |
| Trippett, TM | 1 |
| Bertino, JR | 4 |
| Fleming, GF | 1 |
| Schilsky, RL | 1 |
| Brown, TD | 1 |
| Burris, HA | 1 |
| Havlin, KA | 1 |
| O'Rourke, TJ | 1 |
| Rodriguez, GI | 1 |
| Wall, JG | 1 |
| Weiss, GR | 1 |
| Hudes, GR | 3 |
| LaCreta, F | 2 |
| Walczak, J | 1 |
| Tinsley, P | 1 |
| Litwin, S | 1 |
| Comis, RL | 3 |
| O'Dwyer, PJ | 2 |
| Taguchi, T | 1 |
| Tsukagoshi, S | 1 |
| Furue, H | 1 |
| Niitani, H | 1 |
| Ohta, K | 1 |
| Ariyoshi, H | 1 |
| Hasegawa, K | 1 |
| Majima, H | 1 |
| Nakao, I | 1 |
| Yasutomi, M | 1 |
| Stagg, MP | 1 |
| Diasio, RB | 1 |
| Jenkins, J | 1 |
| Weiss, RB | 1 |
| Balis, F | 1 |
| Drake, JC | 1 |
| Brooks, J | 1 |
| Thomas, R | 1 |
| Curt, GA | 1 |
| Grillo-Lopez, AJ | 2 |
| Catalano, R | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Olver, IN | 1 |
| Reece, P | 1 |
| Morris, R | 1 |
| Friedlander, ML | 1 |
| Grochow, LB | 2 |
| Noe, DA | 2 |
| Ettinger, DS | 2 |
| Donehower, RC | 2 |
| Dole, GB | 1 |
| Rowinsky, EK | 1 |
| Graham, ML | 1 |
| McGuire, WP | 1 |
| Lin, JT | 2 |
| Cashmore, AR | 1 |
| Baker, M | 1 |
| Dreyer, RN | 1 |
| Ernstoff, M | 1 |
| Marsh, JC | 1 |
| Whitfield, LR | 2 |
| Delap, R | 1 |
| Grillo-Lopez, A | 1 |
| Ho, DH | 1 |
| Covington, WP | 1 |
| Legha, SS | 1 |
| Newman, RA | 1 |
| Krakoff, IH | 1 |
| Jolivet, J | 1 |
| Landry, L | 1 |
| Pinard, MF | 1 |
| McCormack, JJ | 2 |
| Tong, WP | 1 |
| Eisenhauer, E | 1 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Leyland-Jones, B | 1 |
| Stewart, JA | 2 |
| Tong, W | 1 |
| Low, JB | 1 |
| Roberts, JD | 1 |
| Blow, A | 1 |
| Haugh, LD | 1 |
| Grove, WR | 1 |
| Lopez, AJ | 1 |
11 reviews available for trimetrexate and Neoplasms
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; | 2021 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
Trimetrexate: a critical appraisal of the phase II clinical trial experience: evidence of drug discovery-clinical development disjunction.
Topics: Animals; Clinical Trials, Phase II as Topic; Dogs; Drug Evaluation, Preclinical; Haplorhini; Humans; | 1994 |
Clinical pharmacokinetics and pharmacology of trimetrexate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response Rel | 1994 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 1996 |
New antifolates in clinical development.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Drugs, Investigational; Folic A | 1995 |
Therapeutic strategies targeting proteins that regulate folate and reduced folate transport.
Topics: Antimetabolites, Antineoplastic; Carrier Proteins; Folate Receptors, GPI-Anchored; Folic Acid; Folic | 1999 |
Antifolates: the next generation.
Topics: Aminopterin; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dr | 1992 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; | 1990 |
Trimetrexate: a second generation folate antagonist in clinical trial.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Quinazolines; Trimetrex | 1987 |
7 trials available for trimetrexate and Neoplasms
| Article | Year |
|---|---|
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Child; Child, Preschool; Female; Follow-U | 1993 |
High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
Topics: Adolescent; Adult; Antidotes; Antimetabolites, Antineoplastic; Child; Child, Preschool; Drug Interac | 1998 |
Pharmacokinetic study of trimetrexate in combination with cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; F | 1991 |
[Phase I study of CI-898. CI-898 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Digestive System Neoplasms; Drug Administratio | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; | 1990 |
Trimetrexate: a second generation folate antagonist in clinical trial.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Quinazolines; Trimetrex | 1987 |
14 other studies available for trimetrexate and Neoplasms
| Article | Year |
|---|---|
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line; Colony-Forming Units Assay; Drug Evaluation, Precl | 1984 |
A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Topics: Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Evaluation; Female; H | 1990 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; I | 1989 |
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Dose-Response Relationship, Drug; Drug Combinations | 1989 |
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Topics: Adult; Aged; Animals; Bone Marrow; Drug Administration Schedule; Drug Combinations; Drug Evaluation; | 1989 |
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoies | 1987 |
Clinical pharmacology of trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Metabolic Clear | 1987 |
A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; I | 1987 |
Trimetrexate: clinical development of a nonclassical antifolate.
Topics: Animals; Biological Availability; Drug Administration Schedule; Drug Evaluation; Folic Acid Antagoni | 1987 |
Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle A | 1988 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
Trimetrexate: overall clinical results.
Topics: Antineoplastic Agents; Drug Resistance; Humans; Neoplasms; Quinazolines; Trimetrexate | 1988 |
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Drug Evaluation; Female; Humans; Male; | 1988 |